Journal of Nuclear Medicine

The new JNM Supplement is online now – “Molecular Imaging of Neurodegeneration: The Way to New Horizons”

Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant 225Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study
68Ga-DOTATATE Prepared from Cyclotron-Produced 68Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients
Open Access Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem

Published Ahead of Print

You have access
Functional imaging of chemo-brain: usefulness of Nuclear Medicine in the fog coming after cancer
Agostino Chiaravalloti, Luca Filippi, Marco Pagani and Orazio Schillaci

Journal of Nuclear Medicine February 2, 2023, jnumed.121.263294; DOI: https://doi.org/10.2967/jnumed.121.263294
You have access
Could FAP-targeted molecular imaging replace FDG for standard-of-care oncologic PET?
Raghava Kashyap and Aravind S Ravi Kumar

Journal of Nuclear Medicine February 2, 2023, jnumed.122.265003; DOI: https://doi.org/10.2967/jnumed.122.265003
You have access
Efficacy and safety of ¹²⁴I-mIBG dosimetry-guided high activity ¹³¹I-mIBG therapy of advanced pheochromocytoma or neuroblastoma
Ines Maric, Manuel Weber, Andre Prochnow, Jochen Schmitz, Nicole Unger, Benedikt M. Schaarschmidt, Thorsten D. Poeppel, Christoph Rischpler, Andreas Bockisch, Ken Herrmann, Walter Jentzen and Wolfgang P. Fendler

Journal of Nuclear Medicine February 2, 2023, jnumed.122.264775; DOI: https://doi.org/10.2967/jnumed.122.264775
Open Access
Signaling Network Response to Alpha-Particle Targeted Therapy with Actinium-225 Labeled Minigastrin Analogue ²²⁵Ac-PP-F11N Reveals Radiosensitizing Potential of HDAC Inhibitors
Yun Qin, Stefan Imobersteg, Stephan Frank, Alain Blanc, Tanja Chiorazzo, Philipp Berger, Roger Schibli, Martin P. Béhé and Michal Grzmil

Journal of Nuclear Medicine February 2, 2023, jnumed.122.264597; DOI: https://doi.org/10.2967/jnumed.122.264597
You have access
An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients
Christian Trapp, Dmytro Oliinyk, Paul Rogowski, Rieke Von Bestenbostel, Ute Ganswindt, Minglun Li, Chukwuka Eze, Peter Bartenstein, Leonie Beyer, Harun Ilhan, Gabriel Sheikh, Lena Unterrainer, Christian Stief, Thilo Westhofen, Wolfgang G. Kunz, Marcus Unterrainer, Claus Belka and Nina-Sophie Schmidt-Hegemann

Journal of Nuclear Medicine February 2, 2023, jnumed.122.265159; DOI: https://doi.org/10.2967/jnumed.122.265159
You have access
Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer.
Valentin al Jalali, Gabriel Wasinger, Sazan Rasul, Bernhard Grubmueller, Beatrix Wulkersdorfer, Theresa Balber, Markus Mitterhauser, Judit Simon, Marcus Hacker, Sharokh Shariat, Gerda Egger and Markus Zeitlinger

Journal of Nuclear Medicine February 2, 2023, jnumed.122.264981; DOI: https://doi.org/10.2967/jnumed.122.264981

About The Journal of Nuclear Medicine

The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and research.

Main menu

User menu

Search

Published Ahead of Print

Featured Articles

About The Journal of Nuclear Medicine

Current issue

Issue highlights